Company news
IN8bio, Inc. news in 2024
IN8bio, Inc.'s news releases, calls and decks from 2024, newest first.
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
December 9, 2024
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
November 24, 2024
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 11, 2024
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
November 11, 2024
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
November 4, 2024
IN8bio Announces Pricing of $12.4 Million Private Placement
September 30, 2024
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
September 3, 2024
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
August 11, 2024
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 7, 2024
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
June 12, 2024
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
June 2, 2024
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
May 22, 2024
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
May 13, 2024
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
May 12, 2024
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 8, 2024
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
April 29, 2024
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
April 23, 2024
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
April 8, 2024
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
March 13, 2024
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
February 13, 2024
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
January 3, 2024
Decks in 2024
- Investor Presentation (2024)
Investor deck · 56 slides · 2024